The Division of Maternal-Fetal Medicine is engaged in clinical, basic bench and epidemiological research as one of its primary missions. Our strength lies in the expertise and diverse interests of our faculty, as well as in the collaborations with multiple other disciplines and departments throughout the School of Medicine, The Bloomberg School of Public Health, and the School of Biomedical Engineering. The strong research infrastructure of the Johns Hopkins University forms a solid foundation for the success of our integrated research program for Maternal-Fetal Medicine.

The Mathioudakis lab is focused on developing and evaluating clinical decision support systems, technology, and mHealth for diabetes prevention and management. Our lab leverages large electronic medical record databases and uses machine learning algorithms and artificial intelligence to identify patterns in clinical care associated with optimal clinical outcomes. We are interested in understanding the role that advanced diabetes technologies can play in improving health outcomes for patients with diabetes. Our lab has published extensively on outcomes related to diabetes prevention and diabetes management and outcomes. Based on data from our long-term (over 10 year) clinic-based prospective cohort study from the Johns Hopkins Multidisciplinary Diabetic Foot and Wound Clinic, we have published extensively on clinical predictors and outcomes of patients with diabetic foot ulcers, focusing specifically on the role that glycemic control plays in patients with this complication. Healthcare disparities exist throughout medicine, but are particularly prominent in diabetes; our lab has evaluated healthcare inequities in diabetes outcomes and is developing and evaluating strategies to overcome them. In addition to identify optimal management approach to diabetes and its complications, our lab is interested in development and evaluation of innovative technology approaches to diabetes prevention.

Research interests in the Matthew McNabney Lab include community-based long-term care.

Work in the Maunank Shah Lab focuses on infectious disease modeling and health economics, and seeks to investigate new strategies for diagnosing HIV and tuberculosis (TB) in areas with limited resources, both domestically and abroad. Our primary focus is TB diagnostics, with studies examining the diagnostic test accuracy, cost-effectiveness and programmatic impact of emerging diagnostics. We have developed mobile health initiatives to incorporate video-based therapy for TB treatment, and we have a longstanding interest in interventions that help to reduce or prevent HIV transmission.

The Maura McGuire Lab focuses on the improvement of quality and safety in ambulatory medicine through care management, point-of-care laboratory testing, and electronic health records and care delivery optimization. We also study the use of assessment and technology to augment learning in health care professionals and primary care physicians.

Our lab evaluates new medications and/or techniques for the treatment of drug use disorder by conducting human laboratory studies to sensitively assess drug effects, and randomized controlled trial evaluations of medications for clinical treatment outcomes. We also focus on the development of outcome measures that are sensitive and clinically relevant.

Dr. Dispenza’s laboratory focuses on allergies and IgE-mediated allergic reactions including anaphylaxis.  Overall goals of the lab include understanding the mechanisms driving anaphylaxis severity and phenotypes, discovering new biomarkers for the accurate diagnosis of anaphylaxis, and developing novel strategies for the prevention of IgE-mediated reactions.  One major project focuses on the prevention of anaphylaxis, for which there are no known reliable preventative therapies.  They found that small molecule inhibitors of the enzyme Bruton’s tyrosine kinase (BTK), which is a key component of the IgE signaling pathway, completely suppress IgE-mediated human mast cell and basophil activation and significantly protect against death from severe anaphylaxis in humanized mice.  Further, in an investigator-initiated clinical trial, they demonstrated in an investigator-initiated trial that treatment with just 2 days of the oral BTK inhibitor acalabrutinib completely prevents clinical reactivity from eating peanut in the majority of peanut-allergic adults and markedly increases the tolerance level of the remainder.  These exciting data suggest that a long sought-after preventative therapy for anaphylaxis may finally be within reach.

Research in the Meredith McCormack Lab deals primarily with pulmonary diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and the role of environmental exposures in lung diseases. We have researched the factors that contribute to inner-city asthma, with a focus on how particulate matter air pollution impacts pulmonary function. We are also part of the LIBERATE clinical study, which is focused on patients who experience difficulty breathing and have been diagnosed with severe emphysema. We also have a longstanding interest in the effects of race/ethnicity, poverty and urbanization on nutrition and food allergies.

A basic and translational science laboratory focused on diseases of platelets. We are interested in learning the physiologic mechanisms of platelet function, characterizing the genetic variants that can cause inherited platelet dysfunction, and developing therapeutics that can modulate platelet function to ameliorate human disease.

The Merkin Center's goal is to advance peripheral neuropathy research, deepen our understanding of these conditions and their causes and develop viable therapies. The center will tackle pressing research questions in peripheral neuropathy, with a particular focus on areas that impede the development of better diagnostic and therapeutic strategies.